Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination With Paclitaxel in Patients With Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry

Trial Profile

A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination With Paclitaxel in Patients With Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2019

At a glance

  • Drugs Paclitaxel (Primary) ; Telaglenastat (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Calithera Biosciences
  • Most Recent Events

    • 08 Feb 2019 Planned primary completion date changed from 31 Oct 2018 to 30 Jun 2019.
    • 07 Aug 2018 According to a Calithera Biosciences media release, based on the preliminary analysis of this study and recent changes in the competitive landscape of TNBC, the company is planning not to pursue a further development of CB-839 plus paclitaxel in TNBC at this time.
    • 01 Aug 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top